About Multiple Sclerosis Foundation

Home > Learn About Multiple Sclerosis > News > Study suggests cyclotide may delay MS symptoms

Study suggests cyclotide may delay MS symptoms


A new study suggests that an orally administered cyclotide may delay and diminish MS symptoms. According to the authors, kalata B1 was shown to silence T-cell proliferation.

Researchers from the Medical University of Vienna wanted to determine the effect of kalata B1 in the mouse model of MS. What they found was that treatment of mice with the cyclotide resulted in a significant delay and diminished symptoms. The oral application of kalata B1 substantially impeded disease progression and did not exhibit adverse effects.

Results of mouse model studies sometimes do not translate to humans and may be years away from being a marketable treatment. However, the researchers are now seeking to develop a safe, orally active cyclotide drug for treating MS. Phase I clinical trial for this could start at the end of 2018.

The findings were published in the journal PNAS.

  Support the MSF
Supporting MSF's programs to help make "a brighter tomorrow" has never been easier.
make a donation 

  Learn About MS
Common symptoms of MS include fatigue, weakness, spasticity, balance problems, bladder and bowel problems, numbness, vision loss, tremors and depression.
learn more 


Unless otherwise specified, all medical content is compiled by MSF staff and reviewed for accuracy by a member of our Medical Advisory Board.

The MSF strives to present clear and unbiased information. This site is partially funded through a grant from Bayer Healthcare, LLC.

© Copyright 2000-2013 Multiple Sclerosis Foundation - All Rights Reserved